These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34380625)

  • 1. A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand.
    Lee SC; Ma JSY; Kim MS; Laborda E; Choi SH; Hampton EN; Yun H; Nunez V; Muldong MT; Wu CN; Ma W; Kulidjian AA; Kane CJ; Klyushnichenko V; Woods AK; Joseph SB; Petrassi M; Wisler J; Li J; Jamieson CAM; Schultz PG; Kim CH; Young TS
    Sci Adv; 2021 Aug; 7(33):. PubMed ID: 34380625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Hernandez-Hoyos G; Sewell T; Bader R; Bannink J; Chenault RA; Daugherty M; Dasovich M; Fang H; Gottschalk R; Kumer J; Miller RE; Ravikumar P; Wiens J; Algate PA; Bienvenue D; McMahan CJ; Natarajan SK; Gross JA; Blankenship JW
    Mol Cancer Ther; 2016 Sep; 15(9):2155-65. PubMed ID: 27406985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
    Dang K; Castello G; Clarke SC; Li Y; Balasubramani A; Boudreau A; Davison L; Harris KE; Pham D; Sankaran P; Ugamraj HS; Deng R; Kwek S; Starzinski A; Iyer S; van Schooten W; Schellenberger U; Sun W; Trinklein ND; Buelow R; Buelow B; Fong L; Dalvi P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
    Deegen P; Thomas O; Nolan-Stevaux O; Li S; Wahl J; Bogner P; Aeffner F; Friedrich M; Liao MZ; Matthes K; Rau D; Rattel B; Raum T; Kufer P; Coxon A; Bailis JM
    Clin Cancer Res; 2021 May; 27(10):2928-2937. PubMed ID: 33504551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
    Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
    Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
    Friedrich M; Raum T; Lutterbuese R; Voelkel M; Deegen P; Rau D; Kischel R; Hoffmann P; Brandl C; Schuhmacher J; Mueller P; Finnern R; Fuergut M; Zopf D; Slootstra JW; Baeuerle PA; Rattel B; Kufer P
    Mol Cancer Ther; 2012 Dec; 11(12):2664-73. PubMed ID: 23041545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
    Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
    Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation.
    Chiu D; Tavaré R; Haber L; Aina OH; Vazzana K; Ram P; Danton M; Finney J; Jalal S; Krueger P; Giurleo JT; Ma D; Smith E; Thurston G; Kirshner JR; Crawford A
    Cancer Immunol Res; 2020 May; 8(5):596-608. PubMed ID: 32184296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
    Nolan-Stevaux O; Li C; Liang L; Zhan J; Estrada J; Osgood T; Li F; Zhang H; Case R; Murawsky CM; Estes B; Moore GL; Bernett MJ; Muchhal U; Desjarlais JR; Staley BK; Stevens J; Cooke KS; Aeffner F; Thomas O; Stieglmaier J; Lee JL; Coxon A; Bailis JM
    Cancer Discov; 2024 Jan; 14(1):90-103. PubMed ID: 37861452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSMA-targeted bispecific Fab conjugates that engage T cells.
    Patterson JT; Isaacson J; Kerwin L; Atassi G; Duggal R; Bresson D; Zhu T; Zhou H; Fu Y; Kaufmann GF
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5490-5495. PubMed ID: 29126850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics.
    Thompson S; Dessi J; Self CH
    MAbs; 2009; 1(4):348-56. PubMed ID: 20068406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
    Wu Z; Guo HF; Xu H; Cheung NV
    Mol Cancer Ther; 2018 Oct; 17(10):2164-2175. PubMed ID: 30082472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
    Yeung YA; Krishnamoorthy V; Dettling D; Sommer C; Poulsen K; Ni I; Pham A; Chen W; Liao-Chan S; Lindquist K; Chin SM; Chunyk AG; Hu W; Sasu B; Chaparro-Riggers J; Djuretic I
    Mol Ther; 2020 Mar; 28(3):889-900. PubMed ID: 31981494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
    Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
    Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.